62 related articles for article (PubMed ID: 12899660)
1. In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes.
Cervenková K; Belejová M; Chmela Z; Rypka M; Riegrová D; Michnová K; Michalíková K; Súrová I; Brejcha A; Hanus J; Cerný B; Fuksová K; Havlícek L; Veselý J
Physiol Res; 2003; 52(4):467-74. PubMed ID: 12899660
[TBL] [Abstract][Full Text] [Related]
2. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route.
Chmela Z; Veselý J; Lemr K; Rypka M; Hanus J; Havlícek L; Krystof V; Michnová L; Fuksová K; Lukes J
Drug Metab Dispos; 2001 Mar; 29(3):326-34. PubMed ID: 11181503
[TBL] [Abstract][Full Text] [Related]
3. In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes.
Rypka M; Veselý J; Chmela Z; Riegrová D; Cervenková K; Havlícek L; Lemr K; Hanus J; Cerný B; Lukes J; Michalíková K
Xenobiotica; 2002 Nov; 32(11):1017-31. PubMed ID: 12487731
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
6. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
[TBL] [Abstract][Full Text] [Related]
10. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Havlícek L; Hanus J; Veselý J; Leclerc S; Meijer L; Shaw G; Strnad M
J Med Chem; 1997 Feb; 40(4):408-12. PubMed ID: 9046330
[TBL] [Abstract][Full Text] [Related]
11. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
12. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
[TBL] [Abstract][Full Text] [Related]
13. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II.
Oh CH; Kim HK; Lee SC; Oh C; Yang BS; Rhee HJ; Cho JH
Arch Pharm (Weinheim); 2001 Nov; 334(11):345-50. PubMed ID: 11822171
[TBL] [Abstract][Full Text] [Related]
15. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Kovárová H; Hajdúch M; Korínková G; Halada P; Krupicková S; Gouldsworthy A; Zhelev N; Strnad M
Electrophoresis; 2000 Nov; 21(17):3757-64. PubMed ID: 11271495
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
17. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Krucher NA; Meijer L; Roberts MH
Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Nutley BP; Raynaud FI; Wilson SC; Fischer PM; Hayes A; Goddard PM; McClue SJ; Jarman M; Lane DP; Workman P
Mol Cancer Ther; 2005 Jan; 4(1):125-39. PubMed ID: 15657360
[TBL] [Abstract][Full Text] [Related]
19. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
20. [Effects of cyclin dependent protein kinase inhibitor olomoucine on the neuronal apoptosis after status epilepticus: experiment with rats].
Du XP; Sun MZ; Yu ZY; Chen HX; Tian DS; Xie MJ; Wang W
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(29):2025-9. PubMed ID: 17925171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
